In the present study we screened the JHDL for compounds that differentially inhibit cancer cell growth in the presence of CDK5 inhibition; tilorone and a tilorone analog were identified as agents that selectively target CDK5-deficient PC3 prostate cancer cells. Here, CDK5 is linked to prostate carcinoma.